School of Medicine
Showing 11-20 of 251 Results
Barry Behr, Ph.D., H.C.L.D.
Professor of Obstetrics and Gynecology (Reproductive Endocrinology and Infertility) at the Stanford University Medical Center
Current Research and Scholarly Interests Development of improved embryo culture conditions in vitro. Blastocyst cultures. Embryo metabolism in vitro. Embryo maternal dialogue. Clinical application and integration of extended embryo culture systems. Monozygotic twinning. Prevention of multiple pregnancy. Sperm motility enhancers. Fluorescent and non-fluorescent markers of sperm morphology and viablility. Oocyte cryopreservation. Fertility preservation. Improving IVF outcome.
Jonathan S. Berek, MD, MMS
Laurie Kraus Lacob Professor
Bio Laurie Kraus Lacob Professor
Stanford University School of Medicine
Director, Stanford Women?s Cancer Center
Senior Advisor, Stanford Cancer Institute
Director, Stanford Health Communication Initiative
Advancing Communication Excellence at Stanford
Stanford Center for Health Education
Office of the Vice Provost for Teaching and Learning
Director, Stanford Health Care Communication Program
Stanford Health Care
Y. Katherine Bianco
Clinical Associate Professor, Obstetrics & Gynecology - Maternal Fetal Medicine
Bio My clinical interest in pregnancies complicated with birth defects has led my underlying research interests in genomic abnormalities in the human trophoblast carrying to faulty placentation. The latter began with initial work during K12 and KO8 funding. I took a great interest in the human placenta as it carries potential advantages over other tissues sources: first, this highly metabolically active organ is the potential source of many transcripts. Second, the placenta forms at a very early stage of embryonic development, potentially allowing detection of primary alterations as compared to secondary changes that may mask the underlying causal phenomena. Finally, studying early placentation may provide targets for development of novel molecular approaches, such as up-regulate or down-regulate genes, the protein products of which could potentially serve as molecular surrogates for diagnosis and treatment of pregnancy complication such as miscarriages, pre-eclampsia, pregnancy induced hypertension and intrauterine growth retardation. This work has led to the first Trisomy 21, Trisomy 18, trisomy 13 cell lines established from human placentas making it possible to apply gene editing in the early stages of human trophoblast development.
As my primary clinical responsibility involves treating patients needing medical care and support through their high risk pregnancies, I am interested in factors that may impact outcomes, such as prenatal screening and diagnosis, maternal heart conditions, labor and delivery management, and safety approaches for the second stage of labor. In investigating length of labor and approaches to shorten the second stage, I have found methods of improving perinatal outcomes in diverse maternal populations.
With regards to my interest in fetal medicine, I have worked in collaboration with other specialists such as radiologists and pediatric cardiologists utilizing imagining studies to assess and determine successful perinatal care and fetal survival.
Associate Professor of Obstetrics and Gynecology (Maternal Fetal Medicine) at the Stanford University Medical Center
Current Research and Scholarly Interests prenatal diagnosis, genetics, clinical obstetrics
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Improving Access to Family Planning Services in Low Resource Settings:
Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs.